270 related articles for article (PubMed ID: 25586538)
1. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
Thomaier L; Darst BF; Jewett P; Hoffmann C; Brown K; Makaram A; Blaes A; Argenta P; Teoh D; Vogel RI
Gynecol Oncol; 2021 Dec; 163(3):578-582. PubMed ID: 34674889
[TBL] [Abstract][Full Text] [Related]
3. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
5. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
6. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
7. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo.
Myftiu B; Hundozi Z; Sermaxhaj F; Blyta A; Shala N; Jashari F; Qorraj Bytyqi H; Hyseni E; Kurtishi I
Med Sci Monit; 2022 Aug; 28():e937856. PubMed ID: 36042691
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
Li Y; Sun Z; Cunningham JM; Aubry MC; Wampfler JA; Croghan GA; Johnson C; Wu D; Aakre JA; Molina J; Wang L; Pankratz VS; Yang P
Clin Cancer Res; 2011 Jun; 17(11):3830-40. PubMed ID: 21636554
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations and patient-reported quality of life among patients with lung cancer.
Sloan JA; de Andrade M; Decker P; Wampfler J; Oswold C; Clark M; Yang P
J Clin Oncol; 2012 May; 30(14):1699-704. PubMed ID: 22454423
[TBL] [Abstract][Full Text] [Related]
11. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
[TBL] [Abstract][Full Text] [Related]
12. Similarities in the Neuropathy Phenotype of Cancer Survivors Who Received Different Classes of Chemotherapy Drugs.
Miaskowski C; Levine JD; Paul SM; Cooper B; Abrams G; Topp K; Cheung S; Henderson-Sabes J; Conley YP; Snowberg K; Alfaro E; Quinn M; Kober KM
J Pain; 2022 Sep; 23(9):1604-1615. PubMed ID: 35533976
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Mahmoudpour SH; Bandapalli OR; da Silva Filho MI; Campo C; Hemminki K; Goldschmidt H; Merz M; Försti A
BMC Cancer; 2018 Aug; 18(1):820. PubMed ID: 30111286
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Kim SH; Kim MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY; Ling H; Lee GW
Am J Clin Oncol; 2015 Jun; 38(3):294-9. PubMed ID: 23689644
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.
Park SJ; Yim GW; Paik H; Lee N; Lee S; Lee M; Kim HS
J Gynecol Oncol; 2021 Sep; 32(5):e73. PubMed ID: 34132071
[TBL] [Abstract][Full Text] [Related]
16. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial.
Lustberg M; Wu X; Fernández-Martínez JL; de Andrés-Galiana EJ; Philips S; Leibowitz J; Schneider B; Sonis S
Support Care Cancer; 2023 Jan; 31(2):139. PubMed ID: 36707490
[TBL] [Abstract][Full Text] [Related]
17. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S
Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768
[TBL] [Abstract][Full Text] [Related]
18. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
19. Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.
Khan Z; Jung M; Crow M; Mohindra R; Maiya V; Kaminker JS; Hackos DH; Chandler GS; McCarthy MI; Bhangale T
Genome Med; 2023 Jun; 15(1):45. PubMed ID: 37344884
[TBL] [Abstract][Full Text] [Related]
20. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
